# Onychomycosis Market

> Onychomycosis Market Research Report Information By Type (Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual Onychomycosis (PSO), Candida Onychomycosis, Others), By Treatment Type (Drug Treatment, Topical Therapy and Others), By End Users (Hospital Pharmacies, Retail Pharmacies, And Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.2%
- **2024:** $ 4.17 Billion
- **2025:** $ 4.39 Billion
- **2035:** $ 7.28 Billion
- **Key Players:** Companies such as Novartis (CH), Bayer (DE), Janssen Pharmaceuticals (US), Galderma (CH), Pfizer (US), Merck & Co. (US), Sanofi (FR), Astellas Pharma (JP), Eli Lilly and Company (US) are some of the major participants in the global market.

**Report ID:** MRFR/Pharma/0832-CR · **Pages:** 122 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/onychomycosis-market-1340

---

## Market Summary

Global Onychomycosis Market Size was valued at USD 4.17 Billion in 2024 & the market is projected to grow from USD 4.387 Billion in 2025 to USD 7.285 Billion by 2035, registering a CAGR of 5.20% during the forecast period 2025–2035. North America led the market with over 45.56% share, generating around USD 1.9 Billion in revenue.
 
Growing awareness of fungal nail infections, aging populations, diabetes, and improved diagnosis are expanding demand for onychomycosis treatments. Advances in oral and topical antifungal therapies are also improving treatment options, supporting broader adoption and sustained market growth across healthcare settings.
 
WHO projects the global population aged 60 years and older to increase from 1.1 billion in 2023 to 1.4 billion by 2030, expanding the demographic at greater risk of onychomycosis and supporting demand for effective antifungal care.

## Market Drivers

### Growing Geriatric Population

The demographic shift towards an aging population is a significant driver for the Onychomycosis Industry. Older adults are more susceptible to onychomycosis due to factors such as reduced immune function and comorbidities. As the global population ages, the prevalence of nail fungal infections is likely to rise, leading to increased demand for effective treatment options.
 
According to recent estimates, the incidence of onychomycosis in the elderly population can reach up to 50%. This trend suggests that the market will need to adapt to cater to the specific needs of this demographic, potentially leading to the development of targeted therapies.

- PubMed evidence shows that onychomycosis prevalence rises substantially with age, reaching at least 20% among people aged 60 years and older and at least 50% among those aged 70 years and older. This elevated burden among older adults strengthens demand for effective antifungal therapies and supports continued treatment-market expansion.

###  

### Rising Healthcare Expenditure

The increase in healthcare expenditure across various regions is contributing to the growth of the Onychomycosis Industry. As individuals allocate more resources towards health and wellness, there is a corresponding rise in spending on dermatological treatments, including those for onychomycosis. This trend is particularly evident in developed economies, where healthcare systems are increasingly prioritizing the treatment of fungal infections.
 
Enhanced access to healthcare services and insurance coverage for antifungal treatments may further stimulate market growth. Consequently, the market is poised to benefit from this upward trajectory in healthcare spending, as more patients seek effective solutions for their nail fungal infections.

- The World Bank's Global Health Expenditure Database tracks current health expenditure across 2000–2024, providing extensive evidence of continued healthcare-resource allocation worldwide. Increasing healthcare investment creates greater capacity for diagnosis, dermatological consultations, prescription medicines, and antifungal treatment access, supporting the broader market for onychomycosis management.

### Emergence of E-commerce Platforms

The emergence of e-commerce platforms is reshaping the distribution landscape of the Onychomycosis Industry. With the increasing penetration of the internet and mobile devices, consumers are now able to access a wide range of antifungal products online. This shift towards digital purchasing is likely to enhance product availability and convenience for patients seeking treatment for onychomycosis.
 
Furthermore, e-commerce platforms often provide detailed product information and customer reviews, which can aid consumers in making informed decisions. As a result, the market may experience growth as more individuals opt for online purchases, thereby expanding the reach of antifungal treatments.

- PubMed research identifies onychomycosis as a common chronic nail disorder and highlights the availability of both oral and topical treatment options. The expanding treatment landscape supports consumer access through multiple channels, including digitally enabled pharmacy services, while greater product availability can encourage patients to seek and continue appropriate antifungal treatment.

### Advancements in Antifungal Treatments

The Onychomycosis Industry is witnessing a surge in advancements in antifungal treatments, which is likely to enhance treatment efficacy and patient compliance. Recent developments in drug formulations, including novel topical and systemic antifungal agents, have shown promising results in clinical trials. For instance, the introduction of new oral antifungal medications has been associated with higher cure rates and reduced treatment durations.
 
This innovation not only addresses the limitations of traditional therapies but also expands the treatment landscape for onychomycosis. As a result, the market is expected to benefit from increased adoption of these advanced treatments, ultimately improving patient outcomes.

- Clinical evidence demonstrates the progress of topical antifungal innovation. In two Phase III studies, efinaconazole 10% achieved mycological cure rates of 55.2% and 53.4%, compared with substantially lower vehicle results, supporting continued development of more effective topical therapies for onychomycosis.

### Increasing Awareness of Onychomycosis

The rising awareness regarding onychomycosis is a pivotal driver for the Onychomycosis Industry. Educational campaigns and health initiatives have been instrumental in informing the public about the symptoms and risks associated with nail fungal infections. This heightened awareness is likely to lead to increased consultations with healthcare professionals, thereby driving demand for effective treatment options.
 
As individuals become more informed, they are more inclined to seek medical advice, which could potentially result in a surge in diagnosed cases. Consequently, the market may experience growth as pharmaceutical companies respond to this demand with innovative therapies and products tailored to treat onychomycosis.

- The CDC estimates that fungal diseases account for approximately 13 million outpatient healthcare visits annually in the United States, while emphasizing the need for improved awareness, testing, and antifungal treatment options. This substantial outpatient burden demonstrates the value of recognizing fungal infections earlier and strengthening treatment-seeking behavior.

## Future Outlook

The Onychomycosis Market size is projected to reach USD 7.285 Billion by 2035, growing at a CAGR of 5.2%, driven by increasing awareness, innovative treatments, and rising prevalence of fungal infections.

**New opportunities:**

- Development of telehealth platforms for remote diagnosis and treatment Investment in advanced antifungal drug formulations Expansion of over-the-counter treatment options in [retail pharmacies](https://www.marketresearchfuture.com/reports/retail-pharmacy-market-22432)

By 2035, the Onychomycosis Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Distal Subungual Onychomycosis (Largest) vs. White Superficial Onychomycosis (Fastest-Growing)

The Distal Subungual Onychomycosis (DSO) holds the largest Onychomycosis Market share at 58%, driven by its prevalence among patients and the ease of diagnosis. In contrast, White Superficial Onychomycosis (WSO) is emerging as a significant contender, appealing to patients due to its less severe manifestations and higher treatment adherence. Other segments, including Proximal Subungual Onychomycosis (PSO), Candida Onychomycosis, and Others, contribute to the overall market but do not hold substantial shares compared to DSO and WSO.
The growth trends within the Onychomycosis Market indicate a rising awareness of fungal infections and advancements in treatment options. WSO is particularly benefiting from innovations in topical treatments, making it more attractive to patients seeking effective solutions. Additionally, the increasing incidence of onychomycosis due to factors like aging populations and compromised immunity is supporting the growth of these segments. As healthcare systems evolve, the focus on preventative care is also expected to enhance market opportunities for all types of onychomycosis.

Novartis reported USD 9.3 billion in core R&D expense in 2024, reflecting substantial investment capacity for innovative medicines. Its global innovation infrastructure supports continued research into therapies addressing high unmet needs, while its medicines reached 296 million patients worldwide during 2024.

### By Treatment Type: Drug Treatment (Largest) vs. Topical Therapy (Fastest-Growing)

The market is primarily divided into three treatment types: Drug Treatment, Topical Therapy, and Others. Among these, Drug Treatment holds the largest Onychomycosis Market share at 62%, primarily due to its broader acceptance and reliance by healthcare providers. This segment encompasses systemic antifungal medications that offer effective solutions for severe cases of onychomycosis. In contrast, Topical Therapy is gaining traction as the fastest-growing segment, driven by advancements in formulation and increased patient preference for less invasive treatments.

Bayer's consumer-health portfolio includes Canesten, an established antifungal brand. Bayer reported 8.9% Consumer Health sales growth in Spain in 2024, reaching EUR 126 million, demonstrating strong demand for accessible dermatological and self-care products that complement prescription treatment options.

### By End User: Hospital Pharmacies (Largest) vs. Retail Pharmacies (Fastest-Growing)

The hospital pharmacies constitute the largest segment, accounting for a significant portion of the total Onychomycosis Market share at 55%. These pharmacies are preferred by healthcare professionals for their accessibility to a comprehensive range of antifungal medications, ensuring patients receive effective treatment plans. [Retail pharmacies](https://www.marketresearchfuture.com/reports/retail-pharmacy-market-22432), on the other hand, are gaining traction as they cater to consumer convenience and accessibility, which is vital for patients seeking over-the-counter solutions and self-medication.

End User: Hospital Pharmacies (Dominant) vs. Retail Pharmacies (Emerging)

Hospital pharmacies dominate the market due to their extensive stock of prescribed antifungal agents and expert pharmacist consultations, which enhance patient compliance and treatment effectiveness. They play a critical role in managing complex cases that require tailored therapeutic regimens. Conversely, retail pharmacies are emerging quickly, driven by the rising trend of self-medication and increased consumer awareness about onychomycosis. Their strategic locations and ability to offer a variety of topical treatments conveniently position them favorably in this growing market segment.

## Regional Market Share Analysis

### North America : Market Leader in Onychomycosis Market

North America leads in the Onychomycosis Market Size, accounting for over 45.56% of the global revenue in 2024. The region's growth is driven by increasing awareness of fungal infections, a rise in the aging population, and advancements in treatment options. Regulatory support from agencies like the FDA has also catalyzed market expansion, facilitating quicker approvals for innovative therapies.

- The CDC estimates that fungal diseases in the United States are associated with approximately 13 million outpatient visits, 130,000 hospitalizations, and 7,300 deaths annually, with an estimated USD 19 billion yearly economic cost. The substantial fungal-disease burden supports continued awareness, diagnosis, and antifungal-treatment demand across North America.

The United States is the primary contributor, with significant market players such as Janssen Pharmaceuticals, Merck & Co., and Pfizer leading the competitive landscape. Canada follows as the second-largest market, benefiting from similar healthcare trends and a growing demand for effective antifungal treatments. The presence of established pharmaceutical companies ensures a robust supply of innovative solutions to meet patient needs.

- GE HealthCare reported USD 19.7 billion in 2024 revenue, with total company orders increasing 3% organically year over year and a 1.05× book-to-bill ratio. Its scale reflects North America's strong healthcare technology and infrastructure environment supporting diagnosis, monitoring, and treatment services.

### Europe : Emerging Market Dynamics

Europe Onychomycosis Market was valued at USD 1.251 Billion in 2024, making it the second-largest regional market with a 30% share. The region's expansion is fueled by increasing healthcare expenditure, a growing elderly population, and heightened awareness of fungal infections. Regulatory bodies like the European Medicines Agency (EMA) are actively promoting the development of new antifungal treatments, which is expected to further enhance market dynamics.

Leading countries include Germany, France, and the UK, where the presence of major pharmaceutical companies such as Bayer and Galderma strengthens the competitive landscape. The market is characterized by a mix of established players and emerging biotech firms, all striving to innovate and provide effective solutions for onychomycosis. The collaborative efforts between public health organizations and private sectors are pivotal in addressing this health concern.

- The European Medicines Agency recommended 114 medicines for marketing authorisation in 2024, including 46 medicines containing new active substances. Additionally, applicants for 60% of medicines receiving positive opinions had obtained scientific advice during development, demonstrating Europe's strong regulatory and innovation ecosystem for pharmaceutical development.

### Asia-Pacific : Rapidly Growing Market Potential

Asia-Pacific is rapidly emerging as a significant player in the onychomycosis market, holding around 20% of the global share. The region's growth is driven by increasing urbanization, rising disposable incomes, and a growing awareness of healthcare issues. Countries like China and India are witnessing a surge in demand for effective antifungal treatments, supported by government initiatives aimed at improving healthcare access. The China market represents the largest individual share in the region, fueled by a burgeoning pharmaceutical sector and an aging population increasingly seeking advanced clinical solutions.

China is the largest market in the region, with a burgeoning pharmaceutical sector that includes key players like Astellas Pharma and Eli Lilly. India follows closely, with a growing number of local manufacturers entering the market. The competitive landscape is becoming increasingly dynamic, with both multinational corporations and local firms striving to capture market share through innovative product offerings and strategic partnerships.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is currently the smallest market for onychomycosis, accounting for about 5% of the global share. However, it presents significant growth potential due to increasing healthcare investments and rising awareness of fungal infections. The demand for effective treatments is expected to rise as healthcare infrastructure improves and access to medications expands across the region.

Countries like South Africa and the UAE are leading the market, with a growing number of healthcare facilities and increasing patient awareness. The competitive landscape is characterized by a mix of local and international players, with opportunities for growth as more companies enter the market to meet the rising demand for antifungal treatments. The region's unique challenges, including varying healthcare regulations, also present opportunities for innovative solutions.

## Competitive Benchmarking

The Onychomycosis Market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Novartis (CH), Bayer (DE), and Janssen Pharmaceuticals (US) are actively engaged in enhancing their product portfolios and expanding their market reach. Novartis (CH) has positioned itself as a leader in antifungal therapies, emphasizing research and development to introduce novel treatments.
 
Meanwhile, Bayer (DE) is leveraging its extensive distribution networks to enhance accessibility to its products, while Janssen Pharmaceuticals (US) focuses on strategic collaborations to bolster its market presence. The competitive structure of the market appears moderately fragmented, with several players vying for market share. Companies are adopting various business tactics, such as localizing manufacturing and optimizing supply chains, to enhance operational efficiency. This collective influence of key players fosters a dynamic environment where innovation and strategic positioning are paramount for success.
 
In August 2025, Novartis (CH) announced a partnership with a leading biotechnology firm to co-develop a new topical antifungal treatment. This collaboration is expected to expedite the development process and enhance the efficacy of treatment options available to patients. The strategic importance of this partnership lies in its potential to address unmet medical needs in the market space, thereby solidifying Novartis's competitive edge. In September 2025, Bayer (DE) launched a digital health initiative aimed at improving patient adherence to treatment regimens for market.
 
This initiative includes a mobile application that provides reminders and educational resources for patients. The strategic significance of this move is twofold: it not only enhances patient engagement but also positions Bayer as a forward-thinking player in the market, leveraging technology to improve health outcomes. In July 2025, Janssen Pharmaceuticals (US) expanded its product line by introducing a new oral antifungal medication specifically targeting market.
 
This launch is particularly noteworthy as it reflects Janssen's commitment to addressing the diverse needs of patients suffering from this condition. The introduction of this medication is likely to enhance the company's market share and reinforce its reputation as a leader in innovative treatment solutions. As of October 2025, the market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence in treatment protocols.
 
Strategic alliances among key players are increasingly shaping the competitive landscape, fostering innovation and enhancing product offerings. Looking ahead, it is anticipated that competitive differentiation will evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability, ultimately benefiting patients and healthcare providers alike.

## Recent News & Developments

- **Q2 2024: FDA Approves New Antifungal Therapy for market** The FDA granted approval to a new antifungal therapy specifically indicated for the treatment of onychomycosis, expanding available options for patients with fungal nail infections. This regulatory milestone is expected to drive innovation and adoption in the sector.[3]

## Report Scope

| MARKET SIZE 2024 | 4.17(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 4.387(USD Billion) |
| MARKET SIZE 2035 | 7.285(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.2% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Novartis (CH), Bayer (DE), Janssen Pharmaceuticals (US), Galderma (CH), Pfizer (US), Merck & Co. (US), Sanofi (FR), Astellas Pharma (JP), Eli Lilly and Company (US) |
| Segments Covered | Type, Treatment Type, End Users, Region |
| Key Market Opportunities | Emergence of novel antifungal therapies and increased awareness drive growth in the Onychomycosis Market. |
| Key Market Dynamics | Rising demand for innovative antifungal treatments drives competition and regulatory scrutiny in the Onychomycosis Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the market?**
A: The market was valued at 4.17 USD Billion in 2024.

**Q: What is the projected market size for Onychomycosis by 2035?**
A: The market is projected to reach 7.285 USD Billion by 2035.

**Q: What is the expected CAGR for the market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 5.2%.

**Q: Which segments are included in the Onychomycosis Market?**
A: Key segments in the global market include Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, and Candida Onychomycosis.

**Q: What are the projected valuations for the Distal Subungual Onychomycosis segment by 2035?**
A: The Distal Subungual Onychomycosis segment is projected to grow from 1.25 USD Billion to 2.25 USD Billion by 2035.

**Q: How does the Drug Treatment segment perform in the Onychomycosis Market?**
A: The Drug Treatment segment is expected to increase from 1.67 USD Billion in 2024 to 2.95 USD Billion by 2035.

**Q: What is the market outlook for retail pharmacies in the Onychomycosis Market?**
A: Retail Pharmacies are projected to grow from 1.5 USD Billion to 2.5 USD Billion by 2035.

**Q: Who are the key players in the Onychomycosis Market?**
A: Key players include Novartis, Bayer, Janssen Pharmaceuticals, Galderma, Pfizer, Merck & Co., Sanofi, Astellas Pharma, and Eli Lilly and Company.

**Q: What is the expected growth for the Others segment in Onychomycosis treatment types?**
A: The Others segment in treatment types is projected to grow from 0.99 USD Billion to 1.83 USD Billion by 2035.

**Q: What is the significance of hospital pharmacies in the Onychomycosis Market?**
A: Hospital Pharmacies are expected to increase from 1.25 USD Billion to 2.25 USD Billion by 2035, indicating their vital role in the market.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/onychomycosis-market-1340*